Concepts (92)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Embolism | 4 | 2019 | 174 | 1.530 |
Why?
|
| Arterial Pressure | 2 | 2025 | 27 | 1.090 |
Why?
|
| Pulmonary Artery | 3 | 2025 | 96 | 1.080 |
Why?
|
| Antihypertensive Agents | 2 | 2025 | 169 | 1.000 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2025 | 489 | 0.830 |
Why?
|
| Thrombolytic Therapy | 2 | 2019 | 191 | 0.580 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2019 | 127 | 0.560 |
Why?
|
| Fibrinolytic Agents | 1 | 2019 | 170 | 0.550 |
Why?
|
| Ventricular Dysfunction, Right | 2 | 2019 | 49 | 0.530 |
Why?
|
| Physicians | 1 | 2022 | 471 | 0.520 |
Why?
|
| Heart Arrest | 1 | 2019 | 173 | 0.500 |
Why?
|
| Echocardiography, Doppler | 1 | 2016 | 133 | 0.490 |
Why?
|
| Heart Ventricles | 2 | 2019 | 261 | 0.480 |
Why?
|
| Hemodynamics | 3 | 2025 | 250 | 0.390 |
Why?
|
| Azathioprine | 1 | 2010 | 27 | 0.320 |
Why?
|
| Gastrointestinal Agents | 1 | 2010 | 26 | 0.320 |
Why?
|
| Hodgkin Disease | 1 | 2010 | 55 | 0.310 |
Why?
|
| Intensive Care Units | 3 | 2022 | 406 | 0.310 |
Why?
|
| Crohn Disease | 1 | 2010 | 110 | 0.290 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 378 | 0.270 |
Why?
|
| Acute Disease | 3 | 2019 | 672 | 0.260 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 865 | 0.230 |
Why?
|
| Middle Aged | 8 | 2025 | 17644 | 0.210 |
Why?
|
| Recovery of Function | 1 | 2025 | 288 | 0.210 |
Why?
|
| Adult | 6 | 2025 | 16837 | 0.210 |
Why?
|
| Vascular Resistance | 2 | 2019 | 48 | 0.190 |
Why?
|
| Male | 9 | 2025 | 29927 | 0.190 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2021 | 15 | 0.180 |
Why?
|
| Humans | 13 | 2025 | 63511 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2025 | 774 | 0.180 |
Why?
|
| Prostaglandins I | 1 | 2020 | 2 | 0.170 |
Why?
|
| Acetamides | 1 | 2020 | 13 | 0.160 |
Why?
|
| Echocardiography | 3 | 2019 | 502 | 0.160 |
Why?
|
| Drug Substitution | 1 | 2020 | 42 | 0.160 |
Why?
|
| Pyrazines | 1 | 2020 | 34 | 0.160 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 182 | 0.160 |
Why?
|
| Female | 9 | 2025 | 32912 | 0.160 |
Why?
|
| Respiratory Insufficiency | 1 | 2021 | 155 | 0.150 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2019 | 5 | 0.150 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2019 | 14 | 0.150 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 65 | 0.150 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 297 | 0.150 |
Why?
|
| Survival Rate | 2 | 2021 | 851 | 0.150 |
Why?
|
| Treatment Outcome | 3 | 2025 | 5699 | 0.150 |
Why?
|
| Hypertension, Pulmonary | 1 | 2019 | 95 | 0.140 |
Why?
|
| Registries | 1 | 2021 | 893 | 0.140 |
Why?
|
| Retrospective Studies | 3 | 2019 | 6673 | 0.140 |
Why?
|
| Heart Function Tests | 1 | 2017 | 15 | 0.130 |
Why?
|
| Hemorrhage | 1 | 2019 | 268 | 0.130 |
Why?
|
| Ventricular Function, Right | 1 | 2017 | 28 | 0.130 |
Why?
|
| Inpatients | 1 | 2019 | 305 | 0.130 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 2462 | 0.120 |
Why?
|
| Ventricular Function, Left | 1 | 2017 | 268 | 0.110 |
Why?
|
| Risk Factors | 1 | 2025 | 5359 | 0.110 |
Why?
|
| Lung | 1 | 2019 | 956 | 0.100 |
Why?
|
| Aged | 6 | 2021 | 14472 | 0.100 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 1655 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2017 | 2082 | 0.080 |
Why?
|
| Infliximab | 1 | 2010 | 50 | 0.080 |
Why?
|
| Fatal Outcome | 1 | 2010 | 125 | 0.080 |
Why?
|
| Immunocompromised Host | 1 | 2010 | 108 | 0.070 |
Why?
|
| Nitrofurantoin | 1 | 2006 | 10 | 0.060 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2006 | 5 | 0.060 |
Why?
|
| Cardiac Catheterization | 2 | 2019 | 286 | 0.060 |
Why?
|
| Liver Failure, Acute | 1 | 2006 | 24 | 0.060 |
Why?
|
| United States | 1 | 2016 | 7852 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2020 | 3301 | 0.050 |
Why?
|
| Saudi Arabia | 1 | 2021 | 7 | 0.050 |
Why?
|
| International Agencies | 1 | 2021 | 7 | 0.050 |
Why?
|
| Receptors, Epoprostenol | 1 | 2020 | 1 | 0.040 |
Why?
|
| Infusions, Parenteral | 1 | 2020 | 22 | 0.040 |
Why?
|
| Iloprost | 1 | 2019 | 3 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2019 | 47 | 0.040 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2019 | 34 | 0.040 |
Why?
|
| Epoprostenol | 1 | 2019 | 15 | 0.040 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2019 | 20 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2019 | 254 | 0.040 |
Why?
|
| International Classification of Diseases | 1 | 2019 | 136 | 0.040 |
Why?
|
| Risk | 1 | 2019 | 378 | 0.040 |
Why?
|
| Critical Illness | 1 | 2021 | 321 | 0.040 |
Why?
|
| Critical Care | 1 | 2021 | 397 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2020 | 572 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2019 | 584 | 0.030 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2019 | 140 | 0.030 |
Why?
|
| Prognosis | 1 | 2021 | 1749 | 0.030 |
Why?
|
| Biomarkers | 1 | 2019 | 1409 | 0.030 |
Why?
|
| Time Factors | 1 | 2020 | 3770 | 0.020 |
Why?
|
| Hospitalization | 1 | 2019 | 1364 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 5474 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 4700 | 0.020 |
Why?
|
| Adolescent | 1 | 2021 | 6248 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 980 | 0.010 |
Why?
|